Wee Joo Chng

Chng Wee Joo

Appointment(s)
  • Professor, Department of Medicine
  • Senior Consultant, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System
Administrative Appointment(s)
  • Director, National University Cancer Institute, Singapore, National University Health System
  • Head, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, National University Health System
  • Deputy Director, Cancer Science Institute of Singapore, National University of Singapore
  • Leader, Haematologic Malignancy Tumour Group, National University Cancer Institute, Singapore, National University Health System
  • Lead, Cancer Summit Research Programme, National University Health System
Academic Qualifications
  • PhD, National University of Singapore, Singapore
  • MBChB, University of Leeds, United Kingdom
  • FRCP, Royal College of Edinburgh, United Kingdom | FRCPath, Royal College of Pathologists, United Kingdom
  • FAMS, Academy of Medicine, Singapore
Research Interest(s)
  • Myeloma
  • Genetics
  • Clinical Trials
  • Leukaemia
  • Lymphoma
  • Haematologic Malignancies
Recent Publications
  • 1. Zhou J, Lu X, Tan TZ, Chng WJ. 2018 Jan. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery. Molecular Oncology. 12(1):33-47. doi: 10.1002/1878-0261.12146.
  • 2. Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C et al. 2017 Dec. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 130(24):2610-2618. doi: 10.1182/blood-2017-06-791228.
  • 3. Ng IKS, Ng C, Low JJ, Chiu L, Seah E, Ng CH, Chng WJ, Yan B, Ban KHK. 2017 Dec. Identifying large indels in targeted next generation sequencing assays for myeloid neoplasms: a cautionary tale of the ZRSR1 pseudogene. Journal of Clinical Pathology. 70(12):1069-1073. doi: 10.1136/jclinpath-2017-204440.
  • 4. Yao L, Mustafa N, Tan EC, Poulsen A, Singh P, Minh-Dao DT, Lee JXT, Ramanujulu PM, Chng WJ, Yen JJY et al. 2017 Oct. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry. 60(20):8336-8357. doi: 10.1021/acs.jmedchem.7b00678.
  • 5. Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S et al. 2017 Sep. Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia and Lymphoma. 1-11. doi: 10.1080/10428194.2017.1376743.